To discuss the effects of apatinib (APa) on proliferation, apoptosis, and immune escape of gastric cancer cells by adjusting the high mobility group box 1 (HMGB1)/receptor for advanced glycosylation end products (RAGE) pathway.

SGC-7901 cells were randomly separated into blank control group, low-dose experimental group (intervention with 20 μmol·L^-1 Apa for 48 hours), medium-dose experimental group (intervention with 40 μmol·L^-1 Apa for 48 hours), high-dose experimental group (intervention with 60 μmol·L^-1 Apa for 48 hours) and HMGB1 group (intervention with 60 μmol·L^-1 Apa combined with 100 ng·mL^-1 HMGB1 recombinant factor for 48 hours). After intervention with APa and human HMGB1 recombinant factor, cell counting kit-8 (CCK-8) method, 5-Ethynyl-2’- deoxyuridine (Edu) staining, and immunofluorescence staining Ki67 were used to measure the proliferation of SGC-7901 cells in each group. Flow cytometry, Hoechst 33342/PI double staining, and immunofluorescence were performed to measure apoptosis of SGC-7901 cells in each group. Western blot was performed to detect the expression of HMGB1/RAGE signaling pathway proteins of SGC-7901 cells in various groups. A co-culture system of activated peripheral blood mononuclear cells (PBMCs) or NK cells with SGC-7901 cells was constructed. After grouping and drug intervention, the CCK-8 method was performed to detect the killing rates of T cells and NK cells against SGC-7901 cells in each group. Flow cytometry was used to measure the proportion of activated CD8⁺T cells in the co culture system of PBMCs and SGC-7901 cells in each group. Immunofluorescence staining was performed to measure the expression of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in the co culture system of PBMC and SGC-7901 cells in various groups. In addition, enzyme linked immunosorbent assay (ELISA) method was used to measure the levels of immune cytokines interleukin (IL)-6, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and IL-2 production in the co culture system of PBMC and SGC-7901 cells.

The Edu positive rates in blank control group, the low-dose experimental group, medium-dose experimental group, high-dose experimental group and HMGB1 group were (86.23±5.30)%, (65.81±4.65)%, (43.16±4.52)%, (20.19±3.79)% and (82.45±5.27)%, respectively; the apoptosis rates were (4.37±1.19)%, (23.05±2.14)%, (41.87±2.69)%, (62.04±3.12)% and (5.91±1.28)%, respectively; the relative expression levels of HMGB1 protein were 1.15±0.07, 0.79±0.05, 0.43±0.04, 0.10±0.02 and 1.13±0.06, respectively; the RAGE protein expression levels were 1.23±0.08, 0.85±0.06, 0.47±0.05, 0.14±0.03 and 1.21±0.07, respectively; the PD-1 positive expression rates were (58.13±3.70)%, (45.37±2.84)%, (32.06±3.01)%, (21.47±2.31)% and (54.87±3.53)%, respectively; the T cell killing rates were (10.12±1.34)%, (23.45±1.62)%, (37.06±2.08)%, (51.29±2.73)% and (12.01±1.61)%, respectively; the proportions of activated CD8⁺T cells were (7.21±0.53)%, (12.42±0.81)%, (17.93±0.75)%, (23.07±0.64)% and (7.93±0.56)%, respectively; the IL-6 production levels were (28.31±3.26), (46.02±4.18), (65.43±3.70), (86.15±4.39) and (31.04±3.48) ng·L^-1, respectively. Compared the blank control group with the low-dose experimental group, medium-dose experimental group and high-dose experimental group, compared the HMGB1 group with the high-dose experimental group, the differences of above indexes were all statistically significant (all P<0.05).

APa can inhibit the proliferation and immune escape of gastric cancer cells, promote their apoptosis, possibly by blocking the activation of the HMGB1/RAGE signaling pathway.

To assess the tablet effect of a high-fat diet on the pharmacokinetics of oral FM888 tablet in healthy Chinese participants. FM888 tablet is a novel highly selective adenylyl cyclase 1 (AC1) antagonist potentially involved in chronic pain treatment by modulation of central plasticity.

A single-center, open-label, randomized, single-dose, two-period crossover trial was conducted. Subjects were randomized 1∶1 to receive 400 mg FM888 tablet under fasting or high-fat meal conditions, then crossed over after a 7-day washout. Plasma FM888 concentrations were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and analyzed by non-compartmental methods using Phoenix WinNonlin 8.3.1.

The C_max of FM888 tablet in the fasting state and after a highfat meal were (175.57±89.51) and (63.74±38.74) ng·mL^-1, respectively; AUC_0-last were (645.84±355.50) and (416.28±245.83) h·ng·mL^-1, respectively; AUC_0-∞ were (698.22±373.46) and (455.36±290.66) h·ng·mL^-1, respectively. Exposure to FM888 tablet was lower under fed conditions than under fasting conditions, with C_max and AUC_0-last reduced to approximately 36.00% and 65.00% of the fasting values, respectively. The geometric mean ratios (fed/fasting) for C_max、AUC_0-last and AUC_0-∞ were 36.86% [90% confidence interval (CI): 28.94%-46.95%], 66.01% (90% CI: 55.72%-78.20%), and 67.39% (90% CI: 55.70%-81.53%), respectively. Mixed-effects modeling confirmed a significant effect of feeding status on key parameters (P<0.05). FM888 tablet was well tolerated; all adverse events were grade 1, with no serious events.

A high-fat meal significantly reduced FM888 bioavailability, indicating a marked food effect. Despite lower exposure, FM888 tablet demonstrated favorable safety and tolerability.

To evaluate the clinical efficacy and safety of palbociclib capsules combined with trastuzumab injection in the treatment of hormone receptor positive (HR+)/human epidermal growth factor receptor 2 positive (HER-2+) breast cancer patients who had progressed after prior trastuzumab therapy.

Patients with HR+/HER-2+ breast cancer were divided into control group and treatment group. The control group was treated with intravenous infusion of trastuzumab injection [the initial dose was 8 mg·kg^-1, administered slowly intravenously on the first day of treatment (infusion time ≥90 min); thereafter, the maintenance dose was 6 mg·kg^-1, with 28 days as one treatment cycle, and intravenous infusion was administered on the first day of each cycle (infusion time ≥30 min)]. The treatment group was treated with trastuzumab injection combined with palbociclib capsules, the administration of trastuzumab was the same as that of the control group, and palbociclib capsules was administered orally. The initial dose was determined based on the patient’s condition, ranging from 125 mg to 100 mg (if the adverse reactions were severe, the dose would be reduced), and the treatment was continued for 21 days, followed by a 7-day withdrawal, with a total of 28 days as one treatment cycle. Both groups were treated for three courses and followed up. The clinical efficacy, tumor markers, serological indicators, immune function, expression of phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) pathway-related proteins, quality of life, safety evaluation and prognosis of the two groups of patients were compared.

A total of 78 patients were enrolled, with 41 cases in the control group and 37 cases in the treatment group. After treatment, the total effective rate of the treatment group and the control group were 40.54% (15 cases/37 cases) and 17.07% (7 cases/41 cases), (P<0.05). The median progression free survival (PFS) of the treatment group and the control group were 24.5 and 14.3 months, respectively; the cancer antigen 15-3 (CA15-3) levels were (36.72±5.64) and (40.92±6.73) IU·mL^-1, respectively; the levles of vascular endothelial growth factor (VEGF) were (86.22±12.32) and (95.26±12.15) pg·mL^-1, respectively; the cluster of differentiation 3 positive (CD3⁺) percentages were (50.16±7.12)% and (46.30±7.16)%, respectively; the relative expression levels of p-AKT protein were 0.58±0.12 and 0.64±0.11, respectively; the short form 36 health survey questionnaire (SF-36) scores werr (72.29±9.49) and (67.18±8.93,) points, respectively. The differences of above indexes were all statistically significant (P<0.05, P<0.01, P<0.001). The overall incidence of drug adverse reactions (including thrombocytopenia, leukopenia, neutropenia, nausea and vomiting, and abnormal liver function) was 72.97% (27 cases/37 cases) in the treatment group and 70.73% (29 cases/41 cases) in the control group, with no statistically significant difference (P>0.05).

Palbociclib capsules combined with trastuzumab injection has a definite therapeutic effect in HR+/HER-2+ breast cancer patients. It can more effectively reduce tumor marker levels, significantly prolong PFS, improve quality of life, and does not increase overall adverse reactions.

To study the bioequivalence of test preparation and reference preparation of pregabalin capsule in Chinese healthy subjects under fasting and fed conditions.

Using a single center, randomized, open, two cycle crossover design, 52 healthy subjects were divided into fasting group and fed group, with 26 cases in each group. The test or reference preparation of pregabalin capsules was orally administered 150 mg once. The blood concentration was determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and pharmacokinetic (PK) parameters were calculated to evaluate the bioequivalence.

The main PK parameters C_max of pregabalin capsule test preparation and reference preparation in the fasting group were (6 722.00±1 390.00) and (6 065.00±1 218.00) ng·mL^-1, respectively; AUC_0-t were (32 570.52±3 877.48) and (32 721.93±4 270.54) ng·h·mL^-1, respectively; AUC_0-∞ were (32 941.98±4 040.07) and (33 097.11±4 428.89) ng·h·mL^-1, respectively; t_max was 0.75 (0.50, 1.75) and 1.00 (0.50, 1.75) h, respectively; the t_1/2 were (5.58±0.74) and (5.55±0.80) h, respectively. The main PK parameters C_max of the test preparation and reference preparation of pregabalin capsules in the fed group were (3 786.00±513.90) and (3 786.00±437.50) ng·ml^-1, respectively; AUC_0-t were (32 760.51±4 250.79) and (31 923.83±3 842.92) ng·h·mL^-1, respectively; AUC_0-∞ were (33 371.21±4 406.02) and (32 519.87±4 050.39) ng·h·mL^-1, respec tively; t_max was 3.50 (2.50, 4.50) and 3.00 (2.50, 4.51) h, respectively; the t_1/2 was (5.95±0.79) and (5.89±0.91) h, respectively. Under fasting or fed conditions, the 90% confidence intervals of the main PK parameters of the test preparation and the reference preparation were both 80.00%-125.00%.

The test preparation and reference preparation of pregabalin capsules are bioequivalent under fasting and fed conditions.

To investigate the inhibitory effect of curcumol on the growth of hepatocellular carcinoma(HCC)cells through sialic acid-binding immunoglobulin-like lectin 15(Siglec-15)and its underlying mechanism.

Bel-7402 and HepG2 cells were randomly divided into control group(normal culture), low-dose experimental group (treated with 50 μmol·L^-1 curcumol for 48 hours), and a high-dose experimental group (treated with 100 μmol·L^-1 curcumol for 48 hours). The proliferative, invasive, and migratory capacities of cells were evaluated through a combination of functional assays, including the methyl thiazolyl tetrazolium (MTT) method for cell viability, Transwell and wound healing assays for migration and invasion, and flow cytometry for additional cellular characteristics. The expression levels of Siglec-15, along with key molecules involved in the phosphatidylinositol 3-kinase (PI3K) and protein kinase B (AKT) signaling cascade, were examined at both the messenger RNA(mRNA) and protein levels. For this purpose, real-time quantitative polymerase chain reaction (RT-qPCR) was employed to assess transcript abundance, while Western blotting was used to determine protein expression.

The cell viability rates in the control, low-dose, and high-dose experimental groups of Bel-7402 cells and HepG2 cells were (100.00±0)%, (72.09±1.07)%, (55.65±2.99)% and (100.00±0)%, (57.38±6.97)%, (44.63±6.04)%, respectively; the apoptosis rates in the corresponding groups of Bel-7402 cells and HepG2 cells were (1.87±0.05)%, (2.77±0.08)%, (4.19±0.11)% and (3.52±0.17)%, (5.46±0.11)%, (6.63±0.16)%, respectively; the wound healing rates (horizontal migration rates) in the corresponding groups of Bel-7402 cells and HepG2 cells were (39.06±0.81)%, (19.20±0.59)%, (8.34±0.89)% and (52.25±1.43)%, (21.10±1.95)%, (15.31±0.80)%, respectively; the vertical migration rates in the corresponding groups of Bel-7402 cells and HepG2 cells were (100.00±0)%, (72.40±4.34)%, (62.47±3.08)% and (100.00±0)%, (60.51±2.62)%, (40.47±2.76)%, respectively. In the control group, low-dose experimental group, and high-dose experimental group of Bel-7402 cells and HepG2 cells, the relative mRNA expression levels of Siglec-15 were 1.00±0.18, 0.89±0.01, 0.69±0.07 and 1.00±0.09, 0.90±0.04, 0.88±0.03, respectively; the relative mRNA expression levels of PI3K were 1.00±0.16, 0.80±0.12, 0.75±0.11 and 1.00±0.16, 0.93±0.08, 0.93±0.04, respectively; the relative mRNA expression levels of AKT were 1.00±0.15, 0.73±0.17, 0.52±0.11 and 1.00±0.21, 0.69±0.06, 0.27±0.05, respectively; the relative protein expression levels of Siglec-15 were 1.05±0.07, 0.91±0.09,0.84±0.07 and 0.99±0.05, 0.80±0.02, 0.64±0.04, respectively; the relative protein expression levels of PI3K were 0.96±0.09, 0.49±0.10, 0.17±0.10 and 1.01±0.03, 0.73±0.03, 0.49±0.03, respectively. The relative protein expression levels of AKT were 0.98±0.04, 0.88±0.08, 0.63±0.04 and 1.06±0.04, 0.92±0.02, 0.67±0.03, respectively. In both cell lines, compared with the control group, the differences in the above indicators between each experimental group and the control group were all statistically significant (all P<0.001).

Curcumol exerts anti-hepatocellular carcinoma effects by downregulating Siglec-15 expression and inhibiting the proliferation and migration of Bel-7402 and HepG2 hepatoma cells.

To investigate the effects of ginsenoside Rb1 on hypoxia/reoxygenation (H/R)-induced injury in human pulmonary endothelial cells (HPECs) and its underlying mechanism.

HPECs were randomly divided into control group(normal culture), model group(subjected to 3 h of hypoxia followed by 7 h of reoxygenation), and experimental group(pretreated with 0.1 μmol·L^-1, 1.0 μmol·L^-1, 10.0 μmol·L^-1 and 100.0 μmol·L^-1 ginsenoside Rb1 for 1 h prior to H/R). Cell viability was assessed using the CCK-8 assay. The levels of inflammatory factors including interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were detected by enzyme-linked immunosorbent assay (ELISA). The intracellular adenosine triphosphate(ATP) content and the activities of mitochondrial respiratory chain complex Ⅰ (complex Ⅰ) and ATP synthase were detected by ELISA . The protein relative expression levels of glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), zonula occludens-1 (ZO-1), vascular endothelial cadherin (VE-cadherin) and ATP synthase F1 subunit delta (ATP5D) were measured by Western blot.

The cell viability of the control group, model group and experimental group(0.1, 1.0, 10.0 and 100.0 μmol·L^-1)were 1.07±0.04, 0.61±0.06, 0.68±0.07, 0.80±0.06, 0.96±0.08 and 0.95±0.09, respectively, among which 10.0 μmol·L^-1 showed the optimal protective effect and this concentration was therefore used for subsequent experimental group. The levels of IL-1β in the control group, model group and experimental group were (136.25±3.61), (200.12±8.56) and (149.50±9.20) ng·L^-1, respectively; the levels of IL-6 were (4.95±0.26), (8.96±0.60) and (6.23±0.34)ng·L^-1, respectively; the levels of TNF-α were (328.66±19.14), (461.54±26.39) and (391.77±17.22) ng·L^-1, respectively; the relative expression levels of GRP78 were 0.84±0.15, 1.45±0.13 and 0.82±0.15, respectively; the relative expression levels of CHOP were 0.66±0.11, 1.20±0.41 and 0.76±0.14, respectively; the relative expression levels of ZO-1 were 0.81±0.11, 0.25±0.07 and 0.84±0.13, respectively; the relative expression levels of VE-cadherin were 0.75±0.12, 0.32±0.09 and 0.73±0.14, respectively; the relative expression levels of ATP5D were 0.88±0.16, 0.26±0.08 and 0.83±0.17, respectively; the activities of mitochondrial respiratory chain complex Ⅰ were 2.12±0.26, 1.40±0.17 and 1.82±0.15, respectively; the activities of ATP synthase were 2.14±0.25, 1.32±0.17 and 1.81±0.18, respectively; the contents of ATP were (86.32±8.50), (52.21±5.62) and (91.12±6.10) μmol·ug^-1 protein, respectively; there were statistically significant differences in the above indicators between the model group and the control group, between the experimental group and the model group (all P<0.05).

Ginsenoside Rb1 may alleviate H/R-induced HPECs injury, inflammatory response, and endoplasmic reticulum stress by improving mitochondrial function and increasing intracellular ATP content, thereby restoring normal cellular function.

To investigate the clinical efficacy of vedolizumab injection combined with mesalazine enteric-coated tablets in the treatment of patients with ulcerative colitis(UC).

Patients with ulcerative colitis (UC) were randomly divided into control group and treatment group using a random number table. The control group received mesalazine enteric-coated tablets: 1 g four times daily during the induction phase (weeks 0-14), and 1 g two to three times daily during the maintenance phase (from week 14 until the end of the study). The treatment group received vedolizumab injection in addition to the same mesalazine regimen as the control group. Vedolizumab was administered via intravenous infusion at a dose of 300 mg at weeks 0, 2, 6, and 14 of treatment. Clinical efficacy, levels of inflammatory factors [C-reactive protein(CRP)], fecal calprotectin], immune microenvironment indicators[T helper 17 (Th17) cells, regulatory T (Treg) cells], intestinal barrier function markers (D-lactate, endotoxin), and serum albumin were compared between the two groups at 6 months of treatment. Safety evaluations were also performed.

A total of 108 patients were screened, with 54 enrolled in each group. In the control group, 5 dropped out, leaving 49 for statistical analysis; in the treatment group, 3 dropped out, leaving 51 for statistical analysis. After 6 months of treatment, the total effective rates in the treatment and control groups were 94.12% (48/51) and 77.55% (38/49) respectively, with the treatment group significantly higher (P<0.05). The CRP levels in the treatment and control groups were (6.75±1.86) and (11.71±2.12) mg·L^-1, respectively; fecal calprotectin levels were (36.93±4.54) and (60.15±7.04) μg·g^-1, respectively; albumin levels in the experimental and control groups were (44.29±5.31) and (37.41±4.62) g·L^-1, respectively; the proportions of Th17 were (2.07±0.26)% and (2.54±0.36)%, respectively; the proportions of Treg were (4.20±0.61)% and (3.58±0.49)%, respectively; the levels of D-lactate were (4.62±0.98) and (6.99±1.42)μg·L^-1, respectively; the levels of endotoxin were (2.97±0.39) and(4.03±0.94)U·mL^-1, respectively. The differences of above indexes were all statistically significant (all P<0.05). Adverse drug reactions (ADRs) in the treatment group included nausea (2 cases), diarrhea (1 case), liver dysfunction (elevated alanine aminotransferase, 2 cases), and rash (2 cases), totaling 7 cases. ADRs in the control group included nausea (1 case), abdominal pain (1 case), kidney dysfunction (mildly elevated serum creatinine, 1 case), and rash (2 cases), totaling 5 cases. The total incidence of ADRs was 13.73% (7cases/51cases) in the treatment group and 10.20% (5cases/49cases) in the control group, with no statistically significant difference (P>0.05).

The combination of vedolizumab injection and mesalazine enteric-coated tablet improves clinical outcomes for ulcerative colitis patients without raising the incidence of adverse drug reactions.

To investigate the clinical efficacy and safety of medroxyprogesterone acetate tablets in the treatment of ovulatory dysfunction-related abnormal uterine bleeding.

Patients with ovulatory dysfunction-related abnormal uterine bleeding were allocated into control group and treatment group based on their treatment regimen. The control group received dydrogesterone tablets (10 mg, twice daily) for 10 days starting from the 14th day of the menstrual cycle. The treatment group received medroxyprogesterone acetate tablets (2 mg, three times daily) for 10 days, also starting from the 14th day of the menstrual cycle. Both groups were treated for three menstrual cycles. The clinical efficacy, recovery indicators, angiogenesis and inflammatory response markers, and safety were compared between the two groups.

A total of 135 cases were included in the analysis, with 64 in the control group and 71 in the treatment group. The overall response rate of treatment group and control group were 88.73% (63 cases/71 cases) and 82.81% (53 cases/64 cases), respectively (P>0.05). After treatment, endometrial thickness of treatment group and control group were (6.78±1.23) and. (7.36±1.48) mm, respectively; menstrual blood loss were (60.83±9.78) and (64.61±9.25) mL, respectively; hemostasis time were (3.55±1.85) and (3.95±1.82) d, respectively; follicle stimulating hormone (FSH) levels were (6.07±0.96) and (6.51±1.05) U·L^-1, respectively; prolactin (PRL) levels were (8.92±1.37) and (9.65±1.49) μg·L^-1, respectively; progesterone (P) levels were (0.87±0.13) and (0.94±0.16) pg·mL^-1, respectively; matrix metalloproteinase 9 (MMP-9) levels were (22.16±3.58) and (23.93±3.71) pg·mL^-1, respectively; activator protein-1 (AP-1) levels were (36.82±4.76) and (39.57±5.37) pg·mL^-1, respectively; prostaglandin I2 (PGI₂) levels were (21.39±3.84) and (23.18±4.06) pg·mL^-1, respectively; angiotensin-Ⅱ (Ang-Ⅱ) levels were (164.47±22.58) and (175.81±35.94) pg·mL^-1, respectively; basic fibroblast growth factor (bFGF) levels were (21.15±3.42) and (19.63±3.08) pg·mL^-1, respectively. Except for hemostasis time, all the above indicators showed statistically significant differences between the two groups (all P<0.05). The incidence of adverse reactions in the treatment group and control group was 8.45% (6 cases/71 cases) and 12.50% (8 cases/64 cases), respectively, with no statistical significance (P>0.05).

Compared with dydrogesterone, medroxyprogesterone acetate tablets demonstrates comparable efficacy and safety in treating ovulatory dysfunction-related abnormal uterine bleeding. However, medroxyprogesterone acetate tablets shows superior effects in improving endometrial thickness, reducing menstrual blood loss, regulating sex hormone levels, modulating angiogenesis-related markers.